MOLTHY: Spanish Study for Molecular Characterization of Thyroid Carcinoma
Study Details
Study Description
Brief Summary
This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation.
Three diagnostic techniques will be performed on formalin-fixed paraffin embedded (FFPE) tumor samples from the study population: immunohistochemistry (IHC), fluorescence by in situ hybridization (FISH) as well as Next-Generation Sequencing (NGS) techniques by means of DNA and RNA analysis (Ion Platform Torrent - Oncomine Focus Assay, 52 gene detection). The results of each patient will be compared in order to correlate the results of each method.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques will be carried out to identify NTRK and RET alterations. NTRK alterations will be identified using IHC techniques (NTRK over-expression), and FISH techniques (break-apart method). RET alterations will also be identified using the FISH technique (break-apart method).
At the same time, DNA and RNA will be extracted for sequencing techniques using the Oncomine Focus Assay platform, including 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions, including NTRK and RET).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Thyroid carcinoma Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types: Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants. Medullary thyroid carcinoma (MTC). |
Other: Immunohistochemistry (IHC)
VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices
Other: Fluorescence In-Situ Hybridization (FISH)
FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)
Other: Oncomine Focus Assay Platform with 52 genes
Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Progression free survival (PFS) [Throughout the study. Approximately 2 years]
Time from start of data capture (retrospectively) to progression disease. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.
- Overall survival (OS) [Throughout the study. Approximately 2 years]
Time from start of data capture (retrospectively) to death. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.
- Objective response rate [Throughout the study. Approximately 2 years]
Response to systemic treatments received if available. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.
- Prevalence of genetic alterations [Throughout the study. Approximately 2 years]
Frequency of genetic alterations in the study population determined by the molecular genetic interventions: IHC, FISH and NGS
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All participants must be over 18 years old
-
Obtaining the informed consent signed by the patient or his legal representative.
-
Have a paraffinized tumor sample available for analysis in the central laboratory, preferably from total thyroidectomy.
-
Life expectancy greater than 6 months.
-
Thyroid carcinoma with a date of initial histological diagnosis before January 1, 2021 of the types:
(1) Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated thyroid carcinomas, and the corresponding different variants. The radio-refractoriness criteria will be defined by medical criteria and / or by decision of the tumor committee (depending on the organization of each hospital) or (2) Medullary thyroid carcinoma (MTC). 6. Potential candidate patients must meet at least one of the following premises:
-
Patients with advanced / metastatic disease in wait & see follow-up.
-
Patients with advanced / metastatic disease currently undergoing treatment or in progression to any type of multikinase inhibitor, such as, for example: sorafenib, lenvatinib, cabozantinib, axitinib, vandetanib, ...
-
Patients with advanced / metastatic disease under treatment or in progression to treatments that inhibit immune checkpoints (anti programed death (PD-1) or its ligand (PD-L1), anti Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), others) or who are participating in clinical trial regimen. They must be patients who have previously progressed to multikinase inhibitors.
Exclusion Criteria:
-
Patients affected by other malignant histologies not mentioned in the previous section (eg melanoma, lymphoma, sarcoma, ...) or benign tumors exclusively of the thyroid gland.
-
Patients with radioiodine sensitive differentiated thyroid carcinoma or anaplastic thyroid carcinomas.
-
Patients with refractory radioiodine differentiated thyroid carcinoma and advanced medullary thyroid carcinomas with the possibility of local ablative treatment with radical or curative intent (surgery, radiosurgery, radio-ablation, ...).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitario Durán i Reinals | L'Hospitalet De Llobregat | Barcelona | Spain | 08908 |
| 2 | Fundació Althaia | Manresa | Barcelona | Spain | 08243 |
| 3 | Consorci Corporació Sanitària Parc Taulí de Sabadell | Sabadell | Barcelona | Spain | 08208 |
| 4 | Hospital Universitario Vall d'Hebron | Barcelona | Spain | 08035 | |
| 5 | Hospital Clínic de Barcelona | Barcelona | Spain | 08036 | |
| 6 | Institut Català d'Oncologia Girona - ICO Girona | Girona | Spain | 17007 | |
| 7 | Hospital Universitario Ramón y Cajal | Madrid | Spain | 28034 | |
| 8 | Hospital Universitario La Paz | Madrid | Spain | 28046 | |
| 9 | Hospital universitario Marqués de Valdecilla | Santander | Spain | 39008 | |
| 10 | Hospital General Universitario de Valencia | Valencia | Spain | 46014 | |
| 11 | Hospital Universitario y Politécnico La Fe | Valencia | Spain | 46026 | |
| 12 | Hospital Universitario Miguel Servet | Zaragoza | Spain | 50009 |
Sponsors and Collaborators
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Investigators
- Principal Investigator: Neus Basté Rotllan, M.D. Ph.D., Hospital Clinic of Barcelona
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TTCC-2020-02